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Abstract
Background: The purpose of this study was to investigate mediators of inflammation and haemostasis in patients
with chronic necrotizing pulmonary aspergillosis (CNPA), a locally, destructive process of the lung due to invasion
by Aspergillus species.
Methods: Measurements of selected biomarkers in 10 patients with CNPA and 19 healthy, matched controls were
performed with enzyme-linked immunosorbent assay (ELISA) and multiplex methodology. The gene expressions of
relevant biomarkers were analyzed with real-time quantitative RT-PCR.
Results: Increased concentrations of circulating mediators of inflammation interleukin (IL)-6, IL-8, RANTES, TNF-α,
ICAM-1 and mediators involved in endothelial activation and thrombosis (vWF, TF and PAI-1) were observed in
patients with CNPA. The concentration of the anti-inflammatory cytokine IL-10 was increased both in plasma and in
PBMC in the patient population. The gene expression of CD40L was decreased in PBMC from the patient group,
accompanied by decreased concentrations of soluble (s) CD40L in the circulation.
Conclusions: The proinflammatory response against Aspergillus may be counteracted by reduced CD40L and
sCD40L, as well as increased IL-10, which may compromise the immune response against Aspergillus in patients
with CNPA.
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Background
The ubiquitous mould Aspergillus fumigatus causes a
variety of clinical syndromes ranging from allergic dis-
ease in immunocompetent individuals to invasive pul-
monary aspergillosis in severely immunocompromised
patients [1,2]. Chronic necrotizing pulmonary aspergil-
losis (CNPA) is a locally destructive process of the lung
due to semi invasive infection by Aspergillus species
often accompanied by development of a fungus ball
(aspergilloma). CNPA which is a relatively uncommon
form of Aspergillus infection, typically occurs as a com-
plication of preexisting chronic lung diseases such as
emphysema, sarcoidosis, tuberculosis sequela and other
fibrotic lung diseases as well as in mildly immunocom-
promised patients e.g. diabetes mellitus, chronic liver
disease and alcoholism [3,4]. The most common symp-
toms are chronic, productive cough with or without
hemoptysis and pleuritic chest pain, but constitutional
symptoms (i.e. weight loss, fever and lack of energy) are
also seen [3-5]. Although a few reports suggest a dysre-
gulated cytokine response and involvement of comple-
ment activation in CNPA [6], little is known about the
immunopathogenic mechanisms of this disorder. More-
over, whereas thrombosis and vascular invasion are
histopathological hallmarks of invasive aspergillosis in
severely immunocompromised patients [7,8], the role of
platelet and endothelial cell activation as well as the
levels of prothrombotic mediators in CNPA are largely
unknown [4,6]. To further elucidate these issues, we
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measured selected biomarkers involved in inflammation
and thrombosis in 10 patients with CNPA and in 19 sex-
and age-matched healthy individuals.
Materials and methods
Patients and controls
Between January 2002 and January 2008, 10 patients re-
ferred to the Department of Respiratory Medicine, Rik-
shospitalet, Oslo University Hospital, where a diagnosis
of CNPA were established, were included in the study.
The study population consisted of two women and eight
men, ranging from 52 to 78 years of age (median
63 years) (Table 1).
The diagnosis of CNPA was established using clinical
examination, radiological manifestations, and microbio-
logical and serological results [9]. Four patients had a
history of CNPA for more than 2 years at the time of
sampling. All patients had apical, pulmonary changes
such as pleural thickening and signs of local parenchy-
mal destruction on radiological examination and asper-
gillomas were present in all cases. Five of the patients
had radiological evidence of fibrosis. Five patients also
used a low dose (5–10 mg) prednisolon on a daily
basis, and three out of ten were on the antifungal drug
voriconazole at the time of sampling. As controls we
included blood samples from 19 sex- and age-matched
apparently healthy (based on disease history and rou-
tine blood tests including C-reactive protein) individuals
[ranging from 50 to 73 years (median 60 years); 11 men
and 8 women] that were recruited from the same part
of Norway as the patients. Except for co-morbidities,
there were no demographic differences between the
patients and controls. Informed consent was obtained
from patients and controls, and the study was approved
by Regional Committee for Medical and Research Eth-
ics, South-East, Norway.
Blood sampling and cell isolation
Platelet-poor plasma and serum were collected and
stored as previously described [10]. Peripheral blood
mononuclear cells (PBMC) were obtained from hepari-
nized blood by Isopaque-Ficoll (Lymphoprep; Axis
Shield, Oslo, Norway) gradient centrifugation and stored
in liquid nitrogen until further analyses.
Measurements of cytokines and markers of platelet and
endothelial activation
Plasma levels of interleukin (IL)-6, IL-8/CXCL8, IL-10,
monocyte chemoattractant protein (MCP)-1/CCL2,
regulated on activation, normal T cell expressed and
secreted RANTES/CCL5 and tumor necrosis factor
(TNF)-α were analyzed by Multiplex technology using a
customized Bio-Plex Pro Human 8-plex express assay
(Bio-Rad Laboratories, Hercules, CA). Serum concentra-
tions of CX3CL1 (fractalkine), intracellular adhesion
molecule (ICAM)-1, vascular cell adhesion molecule
(VCAM)-1, E-selectin, and plasma concentrations of
plasminogen activator inhibitor (PAI)-1 were analyzed
by enzyme immunoassays (EIAs) provided from R&D
Systems (Minneapolis, MN). Plasma concentrations of
tissue factor (TF) and thrombomodulin were analyzed
by EIAs (American Diagnostica, Stamford, CT). Plasma
concentrations of von Willebrand factor (vWF) and
serum concentrations of soluble CD40 ligand (sCD40L)
were measured by EIAs obtained from Dako (Glostrup,
Denmark) and Bender MedSystems (Vienna, Austria),
respectively.
Complement studies
The concentration of mannose-binding lectin (MBL)
was measured by a double antibody enzyme-linked im-
munosorbent assay (ELISA) as previously described [11].
The determination of functional activity of the classical,
Table 1 Characteristics of the patients with chronic necrotizing pulmonary aspergillosis
Patient Sex Age Disease All antifungal medication On antifungals
when tested
Biopsy or BAL1 Serology2
#1 Female 61 Sarcoidosis ITR, VOR No Pos. Neg.
#2 Male 52 AML ITR, VOR No Pos. Pos.
#3 Male 53 Sarcoidosis ITR, VOR No Pos. Pos.
#4 Female 63 Tbc ITR, VOR Yes Neg. Pos.
#5 Male 71 ND VOR Yes Neg. Pos.
#6 Male 78 ND None No Neg. Pos.
#7 Male 78 RA None No Pos. Neg.
#8 Male 63 ND VOR No Pos. Pos.
#9 Male 57 Emphysema FLU, AMB, VOR, CAS Yes Pos. Pos.
#10 Male 65 Sarcoidosis CAS, VOR No Pos. Neg.
AML, treated for acute myelogenic leukemia ten years ago; Tbc, previous pulmonary tuberculosis; ND, no primary pulmonary disorders or pre-disposing
immunodeficiency were detected; RA, rheumatoid arthritis; ITR, itraconazole; VOR, voriconazole; FLU, fluconazole; AMB, amphotericin B; CAS, caspofungin.
1 Culture or through direct microscopy.
2 At time of sampling.
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lectin and alternative complement pathways of human
serum complement, using deposition of the terminal
C5b-9 complex in microtiter-wells as read-out (Wieli-
saW) instead of the traditional red cell hemolytic assays,
was performed as previously described [12].
Real-time quantitative RT-PCR
Total RNA was extracted from PBMC isolated from the
CNPA patients and 10 healthy controls using RNeasy
columns (Qiagen), subjected to DNase I treatment, and
stored in RNA storage solution (Ambion, Austin, TX) at
−80 °C. Due to technical difficulties, RNA from one of
the patients was not obtainable. Primers for IL-6, IL-8,
IL-10, TNF-α, RANTES, CD40, CD40L, ICAM-1, and
PAI-1 were designed using the Primer Express software,
version 2.0 (Applied Biosystems, Foster City, CA). Pri-
mer sequences can be provided by request. Quantifica-
tion of mRNA was performed using the ABI Prism 7500
(Applied Biosystems). Gene expression of the house-
keeping gene β-actin (Applied Biosystems) was used for
normalization.
Statistical analysis
Differences in circulating biomarkers were evaluated by
linear regression with biomarker as dependent variable
and group (i.e. patients vs. controls) and use of voricona-
zole as independent variables in a forced model. Differ-
ences in mRNA levels of the different markers were
analyzed with the Mann–Whitney U test. All p-values
are two-sided and p< 0.05 was considered significant.
Chronic necrotizing aspergillosis is a relatively rare con-
dition, and the present study had an explorative design
looking for rather large differences in a relative small
population without performing any power calculation.
Results
Markers of inflammation and endothelial activation
Several significant differences were observed between
CNPA patients (n = 10) and healthy controls (n = 19)
with respect to inflammatory and anti-inflammatory
mediators as well as markers of endothelial activation.
First, CNPA patients showed increased concentrations
of several circulating inflammatory markers including
cytokines [IL-6 (p< 0.001) and TNF-α (p< 0.01)], che-
mokines [IL-8 (not significant, p = 0.057) and RANTES
(p< 0.05)], and the adhesion molecule ICAM-1
(p< 0.05) (Figure 1). Four patients with a history of
more than 2 years had reduced levels of IL-8 compared
with the other patient population, but the difference did
not reach statistical significance (p = 0.056). mRNA levels
of RANTES were also increased in the CNPA group, al-
though the difference did not reach statistical signifi-
cance (p = 0.05, Figure 2). As for MCP-1 and CX3CL1,
there were no differences between the patients and con-
trols (data not shown).
Second, CNPA patients also had markedly raised levels
of the prototypical anti-inflammatory cytokine IL-10
(p< 0.001) (Figure 1). The significant increase in plasma
levels of IL-10 was accompanied by an increased mRNA
level of this cytokine in PBMC (Figure 2).
Finally, while there was a marked increase in levels of
circulating vWF (p< 0.001) in patients with CNPA com-
pared with healthy controls (Figure 1), other parameters
of endothelial cell activation (i.e., VCAM-1 and
E-selectin) were not different between the two groups
(data not shown).
Markers of haemostasis
CNPA patients had significantly raised plasma levels of
the pro-thrombotic mediators TF (p< 0.001) and PAI-1
(p< 0.001) (Figure 1). In contrast, the anti-thrombotic
mediator thrombomodulin showed no difference be-
tween CNPA patients and controls (data not shown).
CD40/CD40L
Serum levels of sCD40L were significantly decreased
(p< 0.05) in the CNPA group as compared with healthy
controls (Figure 1). Patients with CNPA also had signifi-
cant decreased mRNA levels of CD40L in PBMC
(Figure 2).
Complement parameters in plasma
All patients and controls had normal activity in the clas-
sical and alternative complement pathways with no dif-
ferences between the two groups (data not shown). Two
patients and one healthy control had a total defect in the
lectin pathway with MBL levels <50 ng/mL, but there
were no significant differences in MBL levels between
the groups (data not shown). There were no individuals
in our material who were partly deficient in MBL (50–
400 ng/mL).
Effect of therapy and fibrosis on biomarker levels
All selected biomarkers were evaluated to assess if the
use of voriconazole (n = 3), prednisolon (n = 5), evidence
of fibrosis (n = 5) or duration of disease ≤ 2 years (n = 6)
vs. > 2 years (n = 4) influenced the results. No such
effects were observed (data not shown). However, when
including voriconazol in the analysis as an independent
variable in a forced model, the difference between
patients and controls for IL-8 did not reach statistical
significance (p = 0.057).
Discussion
CNPA is characterized by persistent inflammation
caused by an unresolved infection possibly reflecting an
altered antifungal immune response. Several names have
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been proposed for different entities of this condition [3]
as it is thought to represent a spectrum of diseases de-
pending on the degree of invasion of pulmonary paren-
chyma, formation and expansion of multiple cavities
over time and the development of fibrosis in surround-
ing tissue [13]. The term CNPA is often used to describe
all entities in this spectrum of illness.
CD40-CD40L interaction regulates several aspects of
cell-mediated immunity, including activation of antigen-
presenting cells, CD4+ and CD8+ T cells, and stimulation
of IL-12/IFN-γ production [14,15]. The CD40-CD40L
axis has been implicated in anti-fungal defense mechan-
isms [16-20]. Notably, the patients with CNPA had
decreased expression of the gene encoding CD40L in
PBMC and decreased levels of sCD40L. sCD40L is pri-
marily derived from platelets [21-23]. Since A. fumigatus
has been shown to induce platelet activation [24,25], low
serum sCD40L in CNPA patients could reflect degranu-
lated platelets secondary to chronic activation. On the
other hand, the reduced expression of CD40L in
PBMC may suggest a more general impairment in the
CD40-CD40L axis in patients with CNPA, possibly
contributing to a decreased ability to clear the fungus
in these patients as has been demonstrated in other
mycoses [16-18,20].
A major observation in the present study was the
markedly increased IL-10 levels in the CNPA group as
seen both in serum and mRNA expression in PBMC. IL-
10 may have suppressive effects on the antifungal activ-
ity of mononuclear cells against A. fumigatus in vitro [6],
but the role of IL-10 in pulmonary Aspergillus manifes-
tations is still debated. It is conceivable that high IL-10
levels could contribute to the resolution of the Aspergil-
lus induced pulmonary inflammation, but high IL-10
concentrations have also been associated with develop-
ment of invasive aspergillosis in non-neutropenic im-
munocompromised patients and with colonization with
A. fumigatus and allergic bronchopulmonary aspergil-
losis in patients with cystic fibrosis [26]. It is therefore
tempting to hypothesize that the net effect of the high
IL-10 levels in CNPA patients is to contribute to the
maintenance of persistent Aspergillus infection within
the pulmonary tissue in these patients, inducing a state
of nonresolving inflammation.
We further show that patients with CNPA are charac-
terized by significantly increased serum and plasma
levels of several inflammatory markers including inflam-
matory cytokines (IL-6 and TNF-α), chemokines (IL-8
and RANTES) and the adhesion molecule ICAM-1. The
reduced levels, although not significant, of IL-8 in
Figure 1 Plasma and serum levels of IL-6, IL-10, IL-8, RANTES, TNF-α, ICAM-1, soluble CD40L, vWF, tissue factor (TF), and PAI-1 in
patients with CNPA (n = 10, black columns) and healthy controls (n = 19, white columns). Data are mean± SEM. P- values are adjusted for
the use of voriconazole. *p< 0.05, **p< 0.01 and ***p< 0.001 versus controls.
Figure 2 mRNA expression of IL-6, PAI-1, RANTES, IL-10, IL-8, TNF-a, ICAM-1, CD40, and CD40L in 9 patients with CNPA and 10 healthy
controls as assessed by real-time quantitative RT-PCR. Data are mean± SEM in relation to the control gene β-actin and healthy controls are
normalized equal to 1. *p< 0.05 and **p< 0.01 versus controls.
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patients with a history of CNPA more than 2 years may
reflect a down-regulation of the inflammatory response
with sustained infection. Although CNPA is a localized
disease with only involvement of pulmonary tissue, sev-
eral of the patients have constitutional symptoms which
may be associated with the signs of chronic inflamma-
tion reflected in our findings.
Complement defects, and in particular low levels of
MBL, have also been related to the development of
CNPA [27]. In the present study we did not find any dif-
ferences in MBL levels between CNPA patients and con-
trols. However, in our opinion, the present study is too
small to make any firm conclusion concerning the po-
tential role of MBL.
Aspergillus fumigatus is in general angioinvasive, caus-
ing intravascular thrombosis and dissemination of the
fungus through the blood stream [7,8]. Thrombosis and
vascular events have also been documented in patients
with CNPA [28]. Our population of CNPA patients had
increased levels of the pro-thrombotic mediators TF and
PAI-1, without any changes in the anti-thrombotic medi-
ator thrombomodulin. In addition, the CNPA patients
showed signs of enhanced endothelial cell activation as
assessed by increased vWF levels. The normal concen-
tration of E-selectin might seem in conflict with this
finding, but it has previously been shown that the ex-
pression of E-selectin on the endothelium may be differ-
ently regulated than other markers of endothelial cell
activation [29].
Formulations of amphotericin B are proinflammatory
stimulants of innate immune cells and the echinocan-
dins have been shown to enhance the antifungal proper-
ties of neutrophiles and macrophages [30]. Azoles are
the least active to modulate the host`s antifungal
defences [30], but voriconazole has nevertheless been
shown to induce production of TNF-α in the human,
monocytic cell line THP-1 in vitro [31]. In the present
study, three out of ten patients used voriconazole at the
time of sampling. However, we did not observe any dif-
ferences in the levels of measured biomarkers, although
limited by low numbers, when comparing patients
using voriconazole with those who did not. However,
when including voriconazole as an independent vari-
able, the difference between patients and controls did
not reach statistical significance for IL-8, suggesting
some influence of this medication on the immune re-
sponse in CNPA.
Our findings suggest a possible dysfunction of the
CD40-CD40L axis, thus compromising the immune re-
sponse against Aspergillus in patients with CNPA. Ele-
vated levels of the anti-inflammatory cytokine IL-10 may
well contribute to an impaired antifungal response. Both
findings may predispose to persistence of the fungal in-
fection and unresolved inflammation. CNPA patients
have signs of endothelial activation and a pro-
thrombotic phenotype, possibly contributing to the well
known histopathology of infections with A. fumigatus.
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